Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Summary

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

Eligibility

Inclusion Criteria:

* Participants must agree to follow the reproductive criteria as outlined in the protocol
* Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).

Exclusion Criteria:

* Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
* Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.

Conditions2

Interventions1

Locations17 sites

Find trials near these locations

Related trials

• A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) — Genentech, Inc.
• Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients — Intergroupe Francophone du Myelome
• Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma — YOUNGIL KOH
• Self-administration of Subcutaneous Elranatamab in the Patients' Homes. — Thomas Lund
• The Norwegian Immunotherapy in Multiple Myeloma Study — St. Olavs Hospital
• Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma — Stichting European Myeloma Network
• A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma — Celgene
• A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma — Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Browse More Trials